International pharmaceutical group Recordati has announced the purchase of three Bayer Consumer Health brands for the French market: Transipeg®, TransipegLib® and Colopeg®.

The 2016 net sales of the products in France amount to around €10 million.

Transipeg® and TransipegLib® are macrogol based laxatives for the treatment of symptomatic constipation in adults and Colopeg® is a large volume bowel cleanser indicated in preparation for endoscopic exploration.

Andrea Recordati, CEO and Vice Chairman, said: "We are progressively enhancing our presence in the area of gastroenterology and this line of products provides further product choice for doctors and patients in order to meet their specific needs."